132 related articles for article (PubMed ID: 37952507)
1. The role of podoplanin inhibitors in controlling oral cancer progression.
Sayuddin ENEN; Taher M; Arzmi MH; Burhanudin NA; Rostam MA
Arch Oral Biol; 2024 Jan; 157():105841. PubMed ID: 37952507
[TBL] [Abstract][Full Text] [Related]
2. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
3. Platelet CLEC2-Podoplanin Axis as a Promising Target for Oral Cancer Treatment.
Hwang BO; Park SY; Cho ES; Zhang X; Lee SK; Ahn HJ; Chun KS; Chung WY; Song NY
Front Immunol; 2021; 12():807600. PubMed ID: 34987523
[TBL] [Abstract][Full Text] [Related]
4. Podoplanin expression in oral leukoplakia: tumorigenic role.
de Vicente JC; Rodrigo JP; Rodriguez-Santamarta T; Lequerica-Fernández P; Allonca E; García-Pedrero JM
Oral Oncol; 2013 Jun; 49(6):598-603. PubMed ID: 23473850
[TBL] [Abstract][Full Text] [Related]
5. Effects of Maackia amurensis seed lectin (MASL) on oral squamous cell carcinoma (OSCC) gene expression and transcriptional signaling pathways.
Hamilton KL; Sheehan SA; Retzbach EP; Timmerman CA; Gianneschi GB; Tempera PJ; Balachandran P; Goldberg GS
J Cancer Res Clin Oncol; 2021 Feb; 147(2):445-457. PubMed ID: 33205348
[TBL] [Abstract][Full Text] [Related]
6. Expression of podoplanin in oral premalignant and malignant lesions and its potential as a biomarker.
Logeswari J; Malathi N; Thamizhchelvan H; Sangeetha N; Nirmala SV
Indian J Dent Res; 2014; 25(3):305-10. PubMed ID: 25098985
[TBL] [Abstract][Full Text] [Related]
7. Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity.
Inoue H; Miyazaki Y; Kikuchi K; Yoshida N; Ide F; Ohmori Y; Tomomura A; Sakashita H; Kusama K
Tumour Biol; 2012 Feb; 33(1):183-94. PubMed ID: 22081310
[TBL] [Abstract][Full Text] [Related]
8. Role of podoplanin in potentially malignant disorders and oral squamous cell carcinoma and its correlation with lymphangiogenesis.
Parhar S; Kaur H; Vashist A; Verma S
Indian J Cancer; 2015; 52(4):617-22. PubMed ID: 26960495
[TBL] [Abstract][Full Text] [Related]
9. Positive and negative regulation of podoplanin expression by TGF-β and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines.
Ohta M; Abe A; Ohno F; Hasegawa Y; Tanaka H; Maseki S; Kondo E; Kurita K; Nakanishi H
Oral Oncol; 2013 Jan; 49(1):20-6. PubMed ID: 22840788
[TBL] [Abstract][Full Text] [Related]
10. Podoplanin promotes cell migration via the EGF-Src-Cas pathway in oral squamous cell carcinoma cell lines.
Inoue H; Miyazaki Y; Kikuchi K; Yoshida N; Ide F; Ohmori Y; Tomomura A; Sakashita H; Kusama K
J Oral Sci; 2012 Sep; 54(3):241-50. PubMed ID: 23047035
[TBL] [Abstract][Full Text] [Related]
11. [Podoplanin expression in oral squamous cell carcinoma and leukoplakia and its correlation with lymph vessels density].
Zhang G; Guo ZL; Gao Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 2009 Aug; 44(8):488-91. PubMed ID: 19961757
[TBL] [Abstract][Full Text] [Related]
12. Ebp1 activates podoplanin expression and contributes to oral tumorigenesis.
Mei Y; Zhang P; Zuo H; Clark D; Xia R; Li J; Liu Z; Mao L
Oncogene; 2014 Jul; 33(29):3839-50. PubMed ID: 23975429
[TBL] [Abstract][Full Text] [Related]
13. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
Kato Y; Kaneko MK
Sci Rep; 2014 Aug; 4():5924. PubMed ID: 25080943
[TBL] [Abstract][Full Text] [Related]
14. Podoplanin--a novel marker in oral carcinogenesis.
Swain N; Kumar SV; Routray S; Pathak J; Patel S
Tumour Biol; 2014 Sep; 35(9):8407-13. PubMed ID: 24964963
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome.
Yuan P; Temam S; El-Naggar A; Zhou X; Liu DD; Lee JJ; Mao L
Cancer; 2006 Aug; 107(3):563-9. PubMed ID: 16804930
[TBL] [Abstract][Full Text] [Related]
16. Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target.
Retzbach EP; Sheehan SA; Nevel EM; Batra A; Phi T; Nguyen ATP; Kato Y; Baredes S; Fatahzadeh M; Shienbaum AJ; Goldberg GS
Oral Oncol; 2018 Mar; 78():126-136. PubMed ID: 29496040
[TBL] [Abstract][Full Text] [Related]
17. Podoplanin expressing cancer-associated fibroblasts in oral cancer.
Inoue H; Tsuchiya H; Miyazaki Y; Kikuchi K; Ide F; Sakashita H; Kusama K
Tumour Biol; 2014 Nov; 35(11):11345-52. PubMed ID: 25119595
[TBL] [Abstract][Full Text] [Related]
18. Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials.
Harsha C; Banik K; Ang HL; Girisa S; Vikkurthi R; Parama D; Rana V; Shabnam B; Khatoon E; Kumar AP; Kunnumakkara AB
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32384682
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of podoplanin expression in oral squamous cell carcinoma--a regression model auxiliary to UICC classification.
Seki S; Fujiwara M; Matsuura M; Fujita S; Ikeda H; Umeda M; Asahina I; Ikeda T
Pathol Oncol Res; 2014 Jul; 20(3):521-8. PubMed ID: 24281769
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
